Allison M. Bradbury is an assistant professor in the Department of Pediatrics at Ohio State University and a principal investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute, Nationwide Children’s Hospital.
Bradbury earned her Ph.D. in biomedical sciences from Auburn University with her doctoral research focused on the development of adeno-associated virus (AAV) gene therapy for the GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), which is currently in human clinical trials. Her postdoctoral research was performed at the University of Pennsylvania, where she was awarded a National Institutes of Health (NIH) National Research Service Award (NRSA) Postdoctoral Fellowship. During this time, Bradbury evaluated disease mechanisms and developed gene therapy approaches for globoid cell leukodystrophy, also known as Krabbe disease. She received an NIH Pathway to Independence award (K99/R00) and joined Nationwide Children’s Hospital in January 2020.
The Bradbury laboratory is dedicated to understanding disease mechanisms and developing therapeutic approaches for rare, pediatric neurodegenerative disorders. Advances in AAV vectors have led to safer and more efficient viral vehicles to deliver therapeutic transgenes in a single injection, and gene therapy is now a favorable therapeutic intervention for monogenic diseases. A primary focus of the Bradbury lab is improving AAV targeting of specific cell types to enhance efficiency and safety. The Bradbury lab is translational in nature with a commitment to safely and efficiently moving therapies into the clinic for rare, pediatric disorders.